Question 1

What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?

Accepted Answer

Hi bugg log : Thank you for the question—this is an important consideration. Our primary focus is to bring our product to market successfully and build a sustainable, profitable company. By demonstrating real clinical value and commercial traction, we believe this will naturally open the door to multiple exit opportunities over time. As we scale, this could include a potential IPO or a strategic merger or acquisition with a major player in the radiotherapy or medical device space. Historicall...

Question 2

I am wondering what makes you different then other companies saying they can help cure cancer that is raising now? is anybody on your team fully committed to this company? out of 3 I see. 2 are college professors and one is a founder and CEO of his own company.

Accepted Answer

Hi John, Thank you for the thoughtful question—this is an important point, and I’m glad you raised it. What differentiates TibaRay is that we are not approaching cancer treatment as a concept—we are building the core enabling technology for next-generation radiotherapy. Specifically, our proprietary linear accelerator platform is designed to deliver ultra-high dose rate (FLASH) radiation, which has the potential to significantly reduce damage to healthy tissue while maintaining tumor control....

Question 3

What are the relationships between "Vita Imaging" and "TibaRay" financially, physically, legally, and control wise? How large are the engineering teams? Operations teams? Have either of these groups integrated, qualified, or produced anything? I see a lot of concept and pontif...

Accepted Answer

Great questions—happy to clarify. Vita Imaging and TibaRay are separate companies with no shared ownership or finances. I lead both, but each has its own team, investors, and operations. Strategically, they are complementary: Vita focuses on cancer detection, while TibaRay focuses on treatment. We have dedicated engineering and operations teams working on real hardware and systems—not just concepts. This includes active development, testing, and integration work. We are well beyond the concep...

Question 4

If this entity is losing over $3M per year, when do you plan to become profitable?

Accepted Answer

Hello William: In our space, it’s normal to operate at a loss during the development phase—medical device companies typically take 3–7+ years to mature R&D due to technical complexity as well as regulatory and clinical requirements . The key difference with TibaRay is that we have already largely de-risked the core technology and are now transitioning into commercial deployment through partners and early systems. With commercialization underway, our focus is on scaling revenue, with the g...

Question 5

thanks for swift response! Saturday morning I am making a ton of business investments. few more questions what is your moat? there is a company raising now called CancerVax(stood out to me) I can't tell between you and them which is better. can you tell me the key difference b...

Accepted Answer

Great question—and you’re right, both stories sound compelling. The key difference is that we are solving different problems: - TibaRay: advanced radiation platform (hardware + physics) to directly treat tumors - CancerVax: early-stage biotech developing a cancer vaccine to train the immune system Our moat is in deep engineering and system integration—building high-performance linacs, manufacturing them, and integrating into clinical systems. This is very hard to replicate and has a clearer p...

Invest in TibaRay, Inc.

Patented Radiotherapy Technology Designed to Help Cure Cancer in a FLASH™

$977,953

Updates

TibaRay, Inc.

Quick facts

Team profiles

Featured investor profiles

$977,953

Updates